tiprankstipranks
Royalty Pharma price target lowered to $38 from $40 at BofA
The Fly

Royalty Pharma price target lowered to $38 from $40 at BofA

BofA lowered the firm’s price target on Royalty Pharma to $38 from $40 and keeps a Buy rating on the shares. The firm notes its estimates are largely in-line with the Street for Q1 and 2024, but cites changes in net cash for its lowered target in a Large Cap Biotech and Pharma earnings preview note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles